Drug
Efgartigimod Alfa And Hyaluronidase (human Recombinant)
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Therapy Change | 20 | 102.1 | 107.0 | signal |
| 2 | Eyelid Ptosis | 15 | 72.5 | 75.1 | signal |
| 3 | Choking | 14 | 35.4 | 36.6 | signal |
| 4 | Temperature Intolerance | 5 | 24.1 | 24.3 | signal |
| 5 | Poor Venous Access | 5 | 23.8 | 24.1 | signal |
| 6 | Insurance Issue | 7 | 23.1 | 23.5 | signal |
| 7 | Injection Site Rash | 13 | 21.0 | 21.7 | signal |
| 8 | Drug Effect Less Than Expected | 6 | 20.9 | 21.2 | signal |
| 9 | Therapeutic Response Shortened | 12 | 18.5 | 19.0 | signal |
| 10 | Injection Site Discolouration | 4 | 15.8 | 16.0 | signal |
| 11 | Injection Site Pruritus | 13 | 9.6 | 9.9 | signal |
| 12 | Injection Site Bruising | 15 | 9.3 | 9.6 | signal |
| 13 | Injection Site Erythema | 23 | 9.2 | 9.6 | signal |
| 14 | Syringe Issue | 3 | 8.4 | 8.5 | signal |
| 15 | Needle Issue | 4 | 6.9 | 6.9 | signal |
| 16 | Incorrect Dose Administered By Device | 3 | 5.8 | 5.8 | signal |
| 17 | Device Difficult To Use | 7 | 5.2 | 5.3 | signal |